Gyre Therapeutics (NASDAQ:GYRE) Coverage Initiated by Analysts at HC Wainwright

Key Points

• HC Wainwright has initiated coverage of Gyre Therapeutics (NASDAQ:GYRE), offering a "buy" rating with a price target of $18.00, indicating a potential upside of 119.51%.
• Gyre Therapeutics reported Q2 earnings of $0.02 per share, missing consensus estimates and generated revenue of $26.77 million, below the expected $30.80 million.
• Institutional investors have been actively adjusting their positions in Gyre Therapeutics, with notable increases from firms like Wells Fargo and Bank of America.

HC Wainwright assumed coverage on shares of Gyre Therapeutics (NASDAQ:GYRE - Free Report) in a research report released on Tuesday, Marketbeat reports. The brokerage issued a buy rating and a $18.00 price target on the stock. HC Wainwright also issued estimates for Gyre Therapeutics' Q3 2025 earnings at $0.07 EPS, Q4 2025 earnings at $0.06 EPS, FY2025 earnings at $0.17 EPS, FY2026 earnings at $0.04 EPS and FY2027 earnings at ($0.09) EPS.

Gyre Therapeutics Price Performance

GYRE stock traded down $0.54 during mid-day trading on Tuesday, hitting $7.74. 76,302 shares of the stock were exchanged, compared to its average volume of 89,665. The business has a fifty day moving average price of $7.58 and a 200 day moving average price of $8.84. Gyre Therapeutics has a 12 month low of $6.11 and a 12 month high of $19.00. The stock has a market capitalization of $745.46 million, a price-to-earnings ratio of 774.77 and a beta of 1.80.

Gyre Therapeutics (NASDAQ:GYRE - Get Free Report) last issued its quarterly earnings results on Monday, August 11th. The company reported $0.02 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.03 by ($0.01). Gyre Therapeutics had a return on equity of 7.67% and a net margin of 4.08%.The firm had revenue of $26.77 million for the quarter, compared to the consensus estimate of $30.80 million.

Institutional Investors Weigh In On Gyre Therapeutics

Several hedge funds have recently added to or reduced their stakes in the company. Wells Fargo & Company MN increased its holdings in shares of Gyre Therapeutics by 29.4% in the fourth quarter. Wells Fargo & Company MN now owns 4,016 shares of the company's stock worth $49,000 after buying an additional 913 shares during the period. Barclays PLC increased its holdings in shares of Gyre Therapeutics by 13.5% in the fourth quarter. Barclays PLC now owns 10,543 shares of the company's stock worth $128,000 after buying an additional 1,255 shares during the period. Bank of America Corp DE increased its holdings in shares of Gyre Therapeutics by 28.8% in the second quarter. Bank of America Corp DE now owns 6,277 shares of the company's stock worth $46,000 after buying an additional 1,402 shares during the period. GAMMA Investing LLC increased its holdings in shares of Gyre Therapeutics by 15,083.3% in the first quarter. GAMMA Investing LLC now owns 1,822 shares of the company's stock worth $140,000 after buying an additional 1,810 shares during the period. Finally, Bank of New York Mellon Corp increased its holdings in shares of Gyre Therapeutics by 18.7% in the first quarter. Bank of New York Mellon Corp now owns 16,492 shares of the company's stock worth $127,000 after buying an additional 2,596 shares during the period. Institutional investors own 23.99% of the company's stock.

About Gyre Therapeutics

Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.